Bioxytran (BIXT) FCF Margin (2010 - 2018)

Bioxytran (BIXT) posted FCF Margin of 0.02% for Q2 2018, up 104.1% sequentially from 0.6% in Q1 2018, and up 863.0% YoY from 0.0% in Q2 2017.

Bioxytran (BIXT) FCF Margin (2010 - 2018) Analysis & Trends

Bioxytran has reported FCF Margin for 9 years, with the latest figure at 0.02% in Q2 2018.

Quarterly FCF Margin rose 863.0% year-over-year to 0.02% in Q2 2018, while the trailing twelve-month figure through Jun 2018 was 13.4% (up 2458.0% YoY) and the FY2017 annual result came in at 9.69%, up 751.0% from the prior year.
FCF Margin rose to 0.02% in Q2 2018 per BIXT's latest filing, from 0.6% in the prior quarter.
Over five years, FCF Margin peaked at 142.84% in Q4 2014 and troughed at 122.79% in Q2 2014.
A 5-year average of 7.41% and a median of 2.25% in 2016 frame the typical range for FCF Margin.
The sharpest annual moves came in 2014 and 2015: FCF Margin surged 28752 bps in 2014, then sank 14220 bps in 2015.
Over 5 years, FCF Margin stood at 142.84% in 2014, then slumped by 100 bps to 0.64% in 2015, then tumbled by 2176 bps to 13.2% in 2016, then surged by 103 bps to 0.34% in 2017, then tumbled by 93 bps to 0.02% in 2018.
According to Business Quant data, FCF Margin over the past three periods registered 0.02%, 0.6%, and 0.34% for Q2 2018, Q1 2018, and Q4 2017 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	13.35%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	41.07%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	70.82%
10	Bioxytran	2.52 Mn	2.27 Mn	-	-

Download Data